Imunon, Inc. is a clinical stage oncology drug company. The company is headquartered in Lawrenceville, New Jersey and currently employs 25 full-time employees. The firm is focused on advancing a portfolio of treatments that harness the body’s natural mechanisms across an array of human diseases, constituting a differentiating approach from conventional therapies. The firm is developing its non-viral DNA technology across its modalities. The first modality, TheraPlas, is developed for the gene-based delivery of cytokines and other therapeutic proteins in the treatment of solid tumors. The second modality, PlaCCine, is developed for the gene delivery of viral antigens that can elicit a strong immunological response. The Company’s lead clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer that has completed Phase 2 development. IMNN-001 works by instructing the body to produce safe and durable levels of powerful cancer-fighting molecules, such as interleukin-12 and interferon gamma, at the tumor site.
Follow-Up Questions
Who is the CEO of Imunon Inc?
Dr. Stacy Lindborg is the President of Imunon Inc, joining the firm since 2021.
What is the price performance of IMNN stock?
The current price of IMNN is $4.99, it has increased 0.22% in the last trading day.
What are the primary business themes or industries for Imunon Inc?
Imunon Inc belongs to Biotechnology industry and the sector is Health Care
What is Imunon Inc market cap?
Imunon Inc's current market cap is $12.5M
Is Imunon Inc a buy, sell, or hold?
According to wall street analysts, 5 analysts have made analyst ratings for Imunon Inc, including 2 strong buy, 6 buy, 2 hold, 0 sell, and 2 strong sell
